TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life

References

• Lu R-M, Hwang Y-C, Liu I-J, Lee -C-C, Tsai H-Z, Li H-J, Wu H-C. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. doi:10.1186/s12929-019-0592-z. PMID: 31894001
   PubMed Web of Science ®Google Scholar
• Deshaies RJ. Multispecific drugs herald a new era of biopharmaceutical innovation. Nature. 2020;580(7803):329–20. doi:10.1038/s41586-020-2168-1. PMID: 32296187
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212. doi:10.1080/19420862.2016.1268307. PMID: 8071970
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst H-A, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–31. PMID: 29358182. doi:10.1182/blood-2017-08-798322.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M, Wei A, Dombret H, Foà R, Bassan R, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47. PMID: 28249141. doi:10.1056/NEJMoa1609783.
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Loux N, Dagher I, Vons C, Carey K, Briand P, Hadchouel M, Franco D, Jouanneau J, Schwall R, Weber A. Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met. Cancer Gene Ther. 2003. 10(11): 840–9. doi:10.1038/sj.cgt.7700640. PMID: 14605670.
   Google Scholar
• Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6144–52. doi: 10.1158/1078-0432.CCR-05-1418. PMID: 17062691.
   PubMed Web of Science ®Google Scholar
• Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci. 1998;111(2):237–47. doi:10.1242/jcs.111.2.237. PMID: 9405310
   PubMedGoogle Scholar
• Ohashi K, Marion PL, Nakai H, Meuse L, Cullen JM, Bordier BB, Schwall R, Greenberg HB, Glenn JS, Kay MA. Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nat Med. 2000 Mar;6(3):327–31. doi: 10.1038/73187. PMID: 10700236.
   PubMed Web of Science ®Google Scholar
• Steensgaard J, Johansen AS. Biochemical aspects of immune complex formation and immune complex diseases. Allergy. 1980;35(6):457–72. doi:10.1111/j.1398-9995.1980.tb01794.x. PMID: 6451188
   PubMed Web of Science ®Google Scholar
• Rojko JL, Evans MG, Price SA, Han B, Waine G, DeWitte M, Haynes J, Freimark B, Martin P, Raymond JT, et al. Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related Immune complexes:review and case studies. Toxicol Pathol. 2014;42:725–64. PMID: 24705884. doi:10.1177/0192623314526475.
   PubMed Web of Science ®Google Scholar
• Krishna M, Nadler SG. Immunogenicity to Biotherapeutics – the Role of Anti-drug Immune Complexes. Front Immunol. 2016;7 PMID: 26870037. doi:10.3389/fimmu.2016.00021.
   PubMed Web of Science ®Google Scholar
• Bhatta P, Dave E, Heywood SP, Humphreys DP. 2015. Multispecific antibody constructs. US11345760 BBUS11345760 BBMultispecific antibody constructs. US11345760 BB US11345760 BB.
   Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608. doi:10.1038/s41573-019-0028-1. PMID: 31175342
   PubMed Web of Science ®Google Scholar
• Suzuki M, Kato C, Kato A. Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies. J Toxicol Pathol. 2015;28(3):133–39. doi:10.1293/tox.2015-0031. PMID: 6441475
   PubMed Web of Science ®Google Scholar
• Acheampong DO, Adokoh CK, Ampomah P, Agyirifor DS, Dadzie I, Ackah FA, Asiamah EA. Bispecific Antibodies (bsAbs): promising immunotherapeutic agents for cancer therapy. Protein Pept Lett. 2017;24(5):456–65. doi:10.2174/0929866524666170120095128. PMID: 28117014
   PubMed Web of Science ®Google Scholar
• Dave E, Adams R, Zaccheo O, Carrington B, Compson JE, Dugdale S, Airey M, Malcolm S, Hailu H, Wild G, et al. Fab-dsFv: a bispecific antibody format with extended serum half-life through albumin binding. MAbs. 2016;8(7):1319–35. PMID: 27532598. doi:10.1080/19420862.2016.1210747.
   PubMed Web of Science ®Google Scholar
• Reiter Y, Brinkmann U, Kreitman RJ, Jung S-H, Lee B, Pastan I. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry. 1994;33(18):5451–59. doi:10.1021/bi00184a014. PMID: 7910034
   PubMed Web of Science ®Google Scholar
• Bera TK, Onda M, Brinkmann U, Pastan I. A bivalent disulfide-stabilized fv with improved antigen binding to erbb211. J Mol Biol. 1998;281(3):475–83. doi:10.1006/jmbi.1998.1948. PMID: 9698563
   PubMed Web of Science ®Google Scholar
• Rajagopal V, Pastan I, Kreitman RJ. A form of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs. Protein Engineering Design and Selection. 1997;10(12):1453–59. doi:10.1093/protein/10.12.1453. PMID: 9543007
   Google Scholar
• Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan C-T, Pastan IH, et al. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res. 2013;19(17):4717–27. PMID: 23857604. doi:10.1158/1078-0432.Ccr-12-3891.
   PubMed Web of Science ®Google Scholar
• Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments. J Immunol Methods. 2002;267(2):213–26. doi:10.1016/s0022-1759(02)00148-5. PMID: 12165442
   PubMed Web of Science ®Google Scholar
• Iizuka A, Nonomura C, Ashizawa T, Kondou R, Ohshima K, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Maruyama K, et al. A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody targets human breast cancer. Clin Cancer Res. 2019;25(9):2925–34. PMID: 30737243. doi:10.1158/1078-0432.Ccr-17-3123.
   PubMed Web of Science ®Google Scholar
• Schoonjans R, Willems A, Schoonooghe S, Fiers W, Grooten J, Mertens N. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J Immunol. 2000;165(12):7050–57. doi:10.4049/jimmunol.165.12.7050. PMID: 11120833
   PubMed Web of Science ®Google Scholar
• Schoonooghe S, Burvenich I, Vervoort L, De Vos F, Mertens N, Grooten J. PH1-derived bivalent bibodies and trivalent tribodies bind differentially to shed and tumour cell-associated MUC1. Protein Eng Des Sel. 2010;23(9):721–28. doi:10.1093/protein/gzq044. PMID: 20616115
   PubMed Web of Science ®Google Scholar
• Glorius P, Baerenwaldt A, Kellner C, Staudinger M, Dechant M, Stauch M, Beurskens FJ, Parren PW, Winkel JG, Valerius T, et al. The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells. Leukemia. 2013;27(1):190–201. PMID: 22660187. doi:10.1038/leu.2012.150.
   PubMed Web of Science ®Google Scholar
• Schoonooghe S. Engineering and expression of bibody and tribody constructs in mammalian cells and in the yeast Pichia pastoris. Methods Mol Biol. 2012;899:157–75. PMID: 22735952. doi:10.1007/978-1-61779-921-1_10.
   PubMedGoogle Scholar
• Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT. Unraveling the Interaction between FcRn and Albumin: opportunities for Design of Albumin-Based Therapeutics. Front Immunol. 2014;5:682. PMID: 25674083. doi:10.3389/fimmu.2014.00682.
   PubMed Web of Science ®Google Scholar
• Adams R, Griffin L, Compson JE, Jairaj M, Baker T, Ceska T, West S, Zaccheo O, Dave E, Lawson AD, et al. Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: an investigation into the correlation between affinity and serum half-life. MAbs. 2016;8(7):1336–46. PMID: 27315033. doi:10.1080/19420862.2016.1185581.
   PubMed Web of Science ®Google Scholar
• Webber KO. Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. Mol Immunol. 1995;32(4):249–58. doi:10.1016/0161-5890(94)00150-y. PMID: 7723770
   PubMed Web of Science ®Google Scholar
• Jung S-H, Pastan I, Lee B. Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. Proteins. 1994;19(1):35–47. doi:10.1002/prot.340190106. PMID: 8066084
   PubMed Web of Science ®Google Scholar
• Glockshuber R, Malia M, Pfitzinger I, Plueckthun A. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry. 1990;29(6):1362–67. doi:10.1021/bi00458a002. PMID: 2110478
   PubMed Web of Science ®Google Scholar
• Zhu Z, Presta LG, Zapata G, Carter P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci. 1997;6(4):781–88. doi:10.1002/pro.5560060404. PMID: 9098887
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Reiter Y, Jung SH, Lee B, Pastan I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci U S A. 1993;90(16):7538–42. doi:10.1073/pnas.90.16.7538. 8356052
   PubMed Web of Science ®Google Scholar
• Weatherill EE, Cain KL, Heywood SP, Compson JE, Heads JT, Adams R, Humphreys DP. Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation. Protein Eng Des Sel. 2012;25(7):321–29. doi:10.1093/protein/gzs021. PMID: 22586154
   PubMed Web of Science ®Google Scholar
• Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA. 1992;89:5867–71. doi: 10.1073/pnas.89.13.5867. PMID: 1352878.
   PubMed Web of Science ®Google Scholar
• Demarest SJ, Glaser SM. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel. 2008;11:675–87.
   PubMed Web of Science ®Google Scholar
• Reiter Y, Brinkmann U, Lee B, Pastan I. Engineering antibody Fv fragments for cancer detection and therapy: bisulfide-stabilized Fv fragments. Nat Biotechnol. 1996;14(10):1239–45. doi:10.1038/nbt1096-1239. PMID: 9631086
   PubMed Web of Science ®Google Scholar
• Holliger P, Prospero T, Winter G. ”Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A. 1993;90(14):6444–48. doi:10.1073/pnas.90.14.6444. PMID: 8341653
   PubMed Web of Science ®Google Scholar
• Bhatta P, Humphreys DP. Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies. Antibodies. 2018;7(3). doi:10.3390/antib7030035. PMID: 31544885
   Web of Science ®Google Scholar
• Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, Zhang J, Hoffmann E, Dormeyer W, Stracke J, et al. Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother. 2011;55(5):2369–78. PMID: 21300827. doi:10.1128/aac.00215-10.
   PubMed Web of Science ®Google Scholar
• Zenobia C, Hajishengallis G. Basic biology and role of interleukin-17 in immunity and inflammation. Periodontology 2000. 2015;69(1):142–59. doi:10.1111/prd.12083. PMID: 26252407
   PubMed Web of Science ®Google Scholar
• Zheng S, Shen F, Jones B, Fink D, Geist B, Nnane I, Zhou Z, Hall J, Malaviya R, Ort T, et al. Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A. MAbs. 2020;12(1):1770018. PMID: 32544369. doi:10.1080/19420862.2020.1770018.
   PubMed Web of Science ®Google Scholar
• Hsieh CM, Cuff C, Tarcsa E, Hugunin M. (Abstract) discovery and characterization of ABT-122, An Anti-TNF/IL-17 DVD-Ig(TM) molecule as a potential therapeutic candidate for rheumatoid arthritis. ACR/ARHP Annual Meeting 2013; New Orleans, USA. p. 1427.
   Google Scholar
• Chen D-Y, Chen Y-M, Chen -H-H, Hsieh C-W, Lin -C-C, Lan J-L. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther. 2011;13(4):R126. doi:10.1186/ar3431. PMID: 21801431
   PubMed Web of Science ®Google Scholar
• Humphreys DT, Wilson MR. MODES OF L929 CELL DEATH INDUCED BY TNF-α AND OTHER CYTOTOXIC AGENTS. Cytokine. 1999;11(10):773–82. doi:10.1006/cyto.1998.0492. PMID: 10525316
   PubMed Web of Science ®Google Scholar
• Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151(3):1548–61. PMID: 8393046
   PubMed Web of Science ®Google Scholar
• Gupta RK, Gracias DT, Figueroa DS, Miki H, Miller J, Fung K, Ay F, Burkly L, Croft M. TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy. Sci Immunol. 2021;6(65):eabi8823. doi:10.1126/sciimmunol.abi8823. PMID: 34797693
   PubMed Web of Science ®Google Scholar
• Robert M, Miossec P. IL-17 in Rheumatoid Arthritis and precision medicine: from synovitis expression to circulating bioactive levels. Front Med. 2019;5:364. PMID: 30693283. doi:10.3389/fmed.2018.00364.
   Web of Science ®Google Scholar
• Chen W, Wang Q, Ke Y, Lin J. Neutrophil function in an inflammatory milieu of Rheumatoid Arthritis. J Immunol Res. 2018;2018:8549329. PMID: 30622982. doi:10.1155/2018/8549329.
   PubMed Web of Science ®Google Scholar
• Bhatta P, Whale KD, Sawtell AK, Thompson CL, Rapecki SE, Cook DA, Twomey BM, Mennecozzi M, Starkie LE, Barry EMC, et al. Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries. MAbs. 2021;13(1):1859049. PMID: 33487120. doi:10.1080/19420862.2020.1859049.
   PubMed Web of Science ®Google Scholar
• Zahnd C, Spinelli S, Luginbuhl B, Amstutz P, Cambillau C, Pluckthun A. Directed in vitro evolution and crystallographic analysis of a peptide-binding single chain antibody fragment (scFv) with low picomolar affinity. J Biol Chem. 2004;279(18):18870–77. doi:10.1074/jbc.M309169200. PMID: 14754898
   PubMed Web of Science ®Google Scholar
• Schlereth B. The Yin and yang of two targets and what about immunogenicity? 7th Annual Biologics Symposium; London, UK. 2017.
   Google Scholar
• Steiner D, Merz FW, Sonderegger I, Gulotti-Georgieva M, Villemagne D, Phillips DJ, Forrer P, Stumpp MT, Zitt C, Binz HK. Half-life extension using serum albumin-binding DARPin® domains. Protein Eng Des Sel. 2017;30(9):583–91. doi:10.1093/protein/gzx022. PMID: 29088432
   PubMed Web of Science ®Google Scholar
• Binz HK, Bakker TR, Phillips DJ, Cornelius A, Zitt C, Göttler T, Sigrist G, Fiedler U, Ekawardhani S, Dolado I, et al. Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate. MAbs. 2017;9(8):1262–69. PMID: 29035637. doi:10.1080/19420862.2017.1305529.
   PubMed Web of Science ®Google Scholar
• Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, Tomlinson IM. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel. 2008;21(5):283–88. doi:10.1093/protein/gzm067. PMID: 18387938
   PubMed Web of Science ®Google Scholar
• Xenaki KT, Dorresteijn B, Muns JA, Adamzek K, Doulkeridou S, Houthoff H, Oliveira S, van Bergen En Henegouwen PM. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. Theranostics. 2021;11(11):5525–38. doi:10.7150/thno.57510. PMID: 33859761
   PubMed Web of Science ®Google Scholar
• Pan H, Su Y, Xie Y, Wang W, Qiu W, Chen W, Lu W, Lu Z, Wang W, Shang A. Everestmab, a novel long-acting GLP-1/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effects. Artif Cells, Nanomed Biotechnol. 2020;48(1):854–66. doi:10.1080/21691401.2020.1770268. PMID: 32468873
   PubMed Web of Science ®Google Scholar
• de Smit H, Ackerschott B, Tierney R, Stickings P, Harmsen MM. A novel single-domain antibody multimer that potently neutralizes tetanus neurotoxin. Vaccine X. 2021;8:100099. doi:10.1016/j.jvacx.2021.100099.
   PubMedGoogle Scholar
• Mandrup OA, Ong SC, Lykkemark S, Dinesen A, Rudnik-Jansen I, Dagnæs-Hansen NF, Andersen JT, Alvarez-Vallina L, Howard KA. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. Commun Biol. 2021;4(1):310. doi:10.1038/s42003-021-01790-2. PMID: 33686177
   PubMed Web of Science ®Google Scholar
• Xu T, Ying T, Wang L, Zhang XD, Wang Y, Kang L, Huang T, Cheng L, Wang L, Zhao Q. A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A. Oncotarget. 2017;8(47):81860–72. doi:10.18632/oncotarget.19899. PMID: 29137228
   PubMedGoogle Scholar
• Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, Jawad A, Pathan E, Kinderlerer A, Taylor PC, et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis. 2012;71(10):1741–48. PMID: 22550316. doi:10.1136/annrheumdis-2011-201024.
   PubMed Web of Science ®Google Scholar
• Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W, et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs. 2016;8(1):141–49. PMID: 26390837. doi:10.1080/19420862.2015.1093266.
   PubMed Web of Science ®Google Scholar
• A Study to Investigate the Safety and Efficacy of ABT-122 given with methotrexate in subjects with active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate; [accessed 2016 Nov 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT02141997.
   Google Scholar
• Safety and tolerability study of COVA322 in patients with stable chronic moderate-to-severe plaque psoriasis; [accessed 2016 Mar 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02243787.
   Google Scholar
• Schlereth B. COVA322 case study: development of a novel anti-TNF/IL-17A bispecific FynomAb. 7th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals Lisbon, Portugal, 2015. https://e-i-p.eu/media/pages/symposiums/2015-lisbon/be88af614d-1644227751/bernd-schlereth.pdf.
   Google Scholar
• Kroenke MA, Milton MN, Kumar S, Bame E, White JT. Immunogenicity risk assessment for multi-specific therapeutics. AAPS J. 2021;23(6):115. doi:10.1208/s12248-021-00642-5. PMID: 34741215
   PubMed Web of Science ®Google Scholar
• Kohno T, Tam LT, Stevens SR, Louie JS. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J Investig Dermatol Symp Proc. 2007;12:5–8. doi: 10.1038/sj.jidsymp.5650034. PMID: 17502862.
   PubMedGoogle Scholar
• Aerts NE, De Knop KJ, Leysen J, et al. Increased IL-17 production by peripheral Thelper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology. 2010;49(12):2264–72. doi:10.1093/rheumatology/keq224. PMID: 20724433.
   PubMed Web of Science ®Google Scholar
• Hoefman S, Ottevaere I, Baumeister J, Sargentini-Maier ML. Pre-Clinical Intravenous serum pharmacokinetics of albumin binding and Non-Half-Life extended Nanobodies®. Antibodies. 2015;4(3):141–56. doi:10.3390/antib4030141.
   Web of Science ®Google Scholar
• Hussain H, Patel T, Ozanne AMS, Vito D, Ellis M, Hinchliffe M, Humphreys DP, Stephens PE, Sweeney B, White J, et al. A comparative analysis of recombinant Fab and Full-length antibody production in Chinese hamster ovary cells. Biotechnol Bioeng. 2021;118(12):4815–28. PMID: 34585737. doi:10.1002/bit.27944.
   PubMed Web of Science ®Google Scholar
• Heywood SP, Wild GB. METHOD FOR PROTEIN PURIFICATION. 2016.
   Google Scholar
• Lai P-K, Ghag G, Yu Y, Juan V, Fayadat-Dilman L, Trout BL. Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: experimental assessment and computational predictions of domain interactions. mAbs. 2021;13(1):1991256. doi:10.1080/19420862.2021.1991256. PMID: 34747330
   PubMed Web of Science ®Google Scholar
• Palm T, Sahin E, Gandhi R, Khossravi M. The importance of the concentration-temperature-viscosity relationship for the development of biologics. Bioprocess Int. 2015;13(3).
   Google Scholar
• Tomar DS, Li L, Broulidakis MP, Luksha NG, Burns CT, Singh SK, Kumar S. In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions. MAbs. 2017;9:476–89. PMID: 28125318. doi:10.1080/19420862.2017.1285479.
   PubMed Web of Science ®Google Scholar
• Sawant MS, Streu CN, Wu L, Tessier PM. Toward drug-like multispecific antibodies by design. Int J Mol Sci. 2020;21:7496. 33053650.
   Web of Science ®Google Scholar
• Nie S, Wang Z, Moscoso-Castro M, D’Souza P, Lei C, Xu J, Gu J. Biology drives the discovery of bispecific antibodies as innovative therapeutics. Antib Ther. 2020;3:18–62. doi:10.1093/abt/tbaa003.
   PubMedGoogle Scholar
• Reiter Y, Brinkmann U, Jung SH, Pastan I, Lee B. Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation. Protein Eng. 1995;8:1323–31. PMID: 8869646. doi:10.1093/protein/8.12.1323.
   PubMedGoogle Scholar
• Boss MA, Kenten JH, Wood CR, Emtage JS. Assembly of functional antibodies from immunoglobulin heavy and light chains synthesised in E. coli. Nucleic Acids Res. 1984;12:3791–806. PMID: 6328437. doi:10.1093/nar/12.9.3791.
   PubMed Web of Science ®Google Scholar
• Cabilly S, Riggs AD, Pande H, Shively JE, Holmes WE, Rey M, Perry LJ, Wetzel R, Heyneker HL. Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli. Proc Natl Acad Sci U S A. 1984;81:3273–77. PMID: 6374653. doi:10.1073/pnas.81.11.3273.
   PubMed Web of Science ®Google Scholar
• Huston JS, Mudgett-Hunter M, Tai MS, McCartney J, Warren F, Haber E, Oppermann H. Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol. 1991;203:46–88. PMID: 1762568. doi:10.1016/0076-6879(91)03005-2.
   PubMed Web of Science ®Google Scholar
• Mannik M. Mechanisms of tissue deposition of immune complexes. J Rheumatol Suppl. 1987;14(13):35–42. PMID: 2956419
   PubMedGoogle Scholar
• Mayadas TN, Tsokos GC, Tsuboi N. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation. 2009;120:2012–24. PMID: 19917895. doi:10.1161/circulationaha.108.771170.
   PubMed Web of Science ®Google Scholar
• Chandramohan V, Pegram CN, Piao H, Szafranski SE, Kuan CT, Pastan IH, Bigner DD. Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial. Appl Microbiol Biotechnol. 2017;101:2747–66. PMID: 28013405. doi:10.1007/s00253-016-8063-x.
   PubMed Web of Science ®Google Scholar
• Lin AY, Dinner SN. Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval. Blood Advances. 2019;3:2905–10. PMID: 31594764. doi:10.1182/bloodadvances.2019000507.
   PubMed Web of Science ®Google Scholar
• Alewine C, Ahmad M, Peer CJ, Hu ZI, Lee MJ, Yuno A, Kindrick JD, Thomas A, Steinberg SM, Trepel JB, et al. Phase I/II study of the Mesothelin-targeted immunotoxin LMB-100 with Nab-Paclitaxel for Patients with advanced pancreatic adenocarcinoma. Clin Cancer Res. 2020;26:828–36. PMID: 31792036. doi:10.1158/1078-0432.Ccr-19-2586.
   PubMed Web of Science ®Google Scholar
• Deokar V, Sharma A, Mody R, Volety SM. Comparison of strategies in development and manufacturing of low viscosity, ultra-high concentration Formulation for IgG1 antibody. J Pharm Sci. 2020;109:3579–89. PMID: 32946895. doi:10.1016/j.xphs.2020.09.014.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu Y. Recent progresses of understanding the viscosity of concentrated protein solutions. Curr Opin Chem Eng. 2017;16:48–55. doi:10.1016/j.coche.2017.04.001.
   Web of Science ®Google Scholar
• Zubler RH, Erard F, Lees RK, Van Laer M, Mingari C, Moretta L, MacDonald HR. Mutant EL-4 thymoma cells polyclonally activate murine and human B cells via direct cell interaction. J Immunol. 1985;134:3662–68. PMID: 3886789.
   PubMed Web of Science ®Google Scholar
• Lightwood D, O’Dowd V, Carrington B, Veverka V, Carr MD, Tservistas M, Henry AJ, Smith B, Tyson K, Lamour S, et al. The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation. J Mol Biol. 2013;425:577–93. PMID: 23219467. doi:10.1016/j.jmb.2012.11.036.
   PubMed Web of Science ®Google Scholar
• Adams R, Maroof A, Baker T, Lawson ADG, Oliver R, Paveley R, Rapecki S, Shaw S, Vajjah P, West S, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894. PMID: 32973785. doi:10.3389/fimmu.2020.01894.
   PubMed Web of Science ®Google Scholar
• Engler C, Marillonnet S. Golden Gate cloning. Methods Mol Biol. 2014;1116:119–31. PMID: 24395361. doi:10.1007/978-1-62703-764-8_9.
   PubMedGoogle Scholar
• Grabulovski D, Melkko MS, Mourlane F, Brack SS, Bertschinger J. IL-17 binding compounds and medical uses thereof. 2011.
   Google Scholar
• Ghayur T, Jijie G, Harris M, Goodreau C, Saluja S. Dual specific binding proteins directed against il-1 beta and il-17. 2014.
   Google Scholar
• Cain K, Peters S, Hailu H, Sweeney B, Stephens P, Heads J, Sarkar K, Ventom A, Page C, Dickson A. A CHO cell line engineered to express XBP1 and ERO1-Lα has increased levels of transient protein expression. Biotechnol Prog. 2013;29:697–706. PMID: 23335490. doi:10.1002/btpr.1693.
   PubMed Web of Science ®Google Scholar
• Konarev PV, Volkov SAV VV, Koch MHJ, Svergun DI. PRIMUS: a Windows PC-based system for small-angle scattering data analysis. J Appl Crystallogr. 2003;36:1277–82. doi:10.1107/s0021889803012779.
   Web of Science ®Google Scholar
• Guinier A, Fournet G. Small-angle scattering of X-rays. New York, USA: Wiley; 1955.
   Google Scholar
• Svergun DI. Determination of the regularization parameter in indirect-transform methods using perceptual criteria. Int Union Crystallogr. 1992;25:495–503.
   Google Scholar
• Rambo RP, Tainer JA. Accurate assessment of mass, models and resolution by small-angle scattering. Nature. 2013;496:477–81. PMID: 23619693. doi:10.1038/nature12070.
   PubMed Web of Science ®Google Scholar
• Franke D, Petoukhov MV, Konarev PV, Panjkovich A, Tuukkanen A, Mertens HDT, Kikhney AG, Hajizadeh NR, Franklin JM, Jeffries CM, et al. ATSAS 2.8: a comprehensive data analysis suite for small-angle scattering from macromolecular solutions. J Appl Crystallogr. 2017;50:1212–25. PMID: 28808438. doi:10.1107/S1600576717007786.
   PubMed Web of Science ®Google Scholar
• Panjkovich A, Svergun DI. Deciphering conformational transitions of proteins by small angle X-ray scattering and normal mode analysis. Phys Chem Chem Phys. 2016;18:5707–19. PMID: 26611321. doi:10.1039/c5cp04540a.
   PubMed Web of Science ®Google Scholar
• Schneidman-Duhovny D, Hammel M, Sali A. FoXS: a web server for rapid computation and fitting of SAXS profiles. Nucleic Acids Res. 2010;38:W540–4. PMID: 20507903. doi:10.1093/nar/gkq461.
   PubMed Web of Science ®Google Scholar
• Kikhney AG, Borges CR, Molodenskiy DS, Jeffries CM, Svergun DI. SASBDB: towards an automatically curated and validated repository for biological scattering data. Protein Sci. 2020;29(1):66–75. doi:10.1002/pro.3731. PMID: 31576635
   PubMed Web of Science ®Google Scholar